Entrada Therapeutics, Inc.

TRDA

US29384C1080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:52:53 2024-05-14 EDT			5-day change	1st Jan Change
14.76 ^USD	+5.02%		+6.12%	-2.39%

05-07	Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-13	Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Entrada Therapeutics, Inc. cancelled the transaction announced on December 7, 2022

December 06, 2023

On December 7, 2023, Entrada Therapeutics, Inc. canceled the transaction.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	VERTEX PHARMACEUTICALS INCORPORATED	425.4 USD	-1.07%	+3.81%	111B
	ENTRADA THERAPEUTICS, INC.	14.76 USD	+5.02%	+6.12%	446M

Latest news about Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
North American Morning Briefing : Stock Futures -2-	03-11	DJ
Oppenheimer Starts Entrada Therapeutics With Outperform Rating, Price Target is $22	01-05	MT
Entrada Therapeutics Adds President Role to COO Nathan Dowden	01-03	MT
Entrada Therapeutics Adds President Role to COO Nathan Dowden	01-03	MT
Sector Update: Health Care Stocks Gain Pre-Bell Wednesday	01-03	MT
Entrada Therapeutics Promotes Nathan J. Dowden to President	01-03	CI
Entrada Therapeutics, Inc. cancelled the transaction announced on December 7, 2022	12-06	CI
Entrada Therapeutics, Inc. Announces Board Changes	12-06	CI
HC Wainwright Adjusts Entrada Therapeutics' Price Target to $20 From $25, Maintains Buy Rating	11-27	MT
US Equity Markets Close Higher Wednesday Following Consumer Sentiment Data	11-22	MT
Sector Update: Health Care Stocks Advance Late Afternoon	11-22	MT
Health-Related Stocks Extend Gains -- Health Care Roundup	11-22	DJ
Top Midday Decliners	11-22	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	11-22	MT
Entrada Therapeutics Shares Tumble 27% After FDA Keeps Clinical Hold	11-22	DJ
Entrada Therapeutics Says FDA Declined to Lift Clinical Hold on Application for Phase 1 Duchenne Muscular Dystrophy Trial	11-22	MT
Entrada : FDA Declines to Lift Hold on Duchenne Study	11-22	DJ
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy	11-22	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Entrada Therapeutics, Inc. Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	23-09-21	CI
Entrada Therapeutics, Inc. Appoints Gina Chapman to its Board of Directors, Effective September 1, 2023	23-08-10	CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI

Chart Entrada Therapeutics, Inc.

Duration

Period

More charts

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Companyâs Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Entrada Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.05 USD

Average target price

21 USD

Spread / Average Target

+49.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENTRADA THERAPEUTICS, INC.	-2.39%	446M
VERTEX PHARMACEUTICALS INCORPORATED	+4.67%	111B
REGENERON PHARMACEUTICALS, INC.	+11.01%	105B
BIONTECH SE	-12.31%	22.34B
ARGENX SE	-3.81%	21.93B
GENMAB A/S	-6.08%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-9.92%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.06%	12.45B

Bio Therapeutic Drugs